Table 1 The dose design and participant allocation of KJ103 in single ascending-dose studies.

From: Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials

Dose group

Dose

No. of healthy participants (China, SHBJ-2021-002)

No. of healthy participants (New Zealand, SHBJ-2021-001)

KJ103

Placebo

KJ103

Placebo

(Normal Saline)

(Normal Saline)

1

0.01 mg/kg

2

0

2

0

2

0.04 mg/kg

6

2

6

2

3

0.12 mg/kg

6

2

6

2

4

0.25 mg/kg

6

2

6

2

5

0.40 mg/kg

6

2

6

2

Total

26

8

26

8

Back to article page